Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3.
暂无分享,去创建一个
Walter Kolch | Katrina Stevenson | W. Kolch | A. Bilsland | Katrina Stevenson | Stuart P. Atkinson | W. Keith | Alan E Bilsland | Stuart Atkinson | W Nicol Keith
[1] D. Mukhopadhyay,et al. Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ* , 1998, The Journal of Biological Chemistry.
[2] R. Perona,et al. Cisplatin induces a persistent activation of JNK that is related to cell death , 1998, Oncogene.
[3] T. Vulliamy,et al. A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria , 2004, BMC blood disorders.
[4] R. Glasspool,et al. Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. , 2000, Neoplasia.
[5] Q. Xu,et al. Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium , 2000, The Journal of Biological Chemistry.
[6] W. Folk,et al. MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. , 2004, Blood.
[7] A. V. D. Van Der Zee,et al. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. , 2001, Cancer research.
[8] February 1 , 1966 .
[9] S. Kaye,et al. Is small cell lung cancer the perfect target for anti-telomerase treatment? , 1999, Carcinogenesis.
[10] J. Riou,et al. Telomerase: a therapeutic target for the third millennium? , 2000, Critical reviews in oncology/hematology.
[11] S. Kaye,et al. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization , 1998, Oncogene.
[12] J. Shay,et al. Telomerase inhibitors. , 2001, Trends in biotechnology.
[13] A. V. D. Van Der Zee,et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.
[14] T. Vulliamy,et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita , 2001, Nature.
[15] E. Yazlovitskaya,et al. Cisplatin‐induced response of c‐jun N‐terminal kinase 1 and extracellular signal‐regulated protein kinases 1 and 2 in a series of cisplatin‐resistant ovarian carcinoma cell lines , 2000, Molecular carcinogenesis.
[16] I. Ganly,et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase , 2003, Oncogene.
[17] J. Merchant,et al. EGF stimulates gastrin promoter through activation of Sp1 kinase activity. , 2000, American journal of physiology. Cell physiology.
[18] R. DePinho,et al. Essential role of mouse telomerase in highly proliferative organs , 1998, Nature.
[19] R. Tjian,et al. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase , 1990, Cell.
[20] Xiao-Fan Wang,et al. Transcriptional Activation of p 21 waf 1 / cip 1 by Alkylphospholipids : Role of the Mitogen-Activated Protein Kinase Pathway in the Transactivation of the Human p 21 waf 1 / cip 1 Promoter by Sp 1 , 2004 .
[21] R. W. Leggett,et al. Casein Kinase II-mediated Phosphorylation of the C Terminus of Sp1 Decreases Its DNA Binding Activity* , 1997, The Journal of Biological Chemistry.
[22] D. Adams,et al. The liver: a model of organ-specific lymphocyte recruitment , 2002, Expert Reviews in Molecular Medicine.
[23] R. Glasspool,et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954 , 2001, Oncogene.
[24] Jiangqin Zhao,et al. MDM2 negatively regulates the human telomerase RNA gene promoter , 2005, BMC Cancer.
[25] E. K. Parkinson,et al. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer , 1997, Oncogene.
[26] J. Pouysségur,et al. Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases , 2002, The Journal of Biological Chemistry.
[27] María A Blasco,et al. Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.
[28] R. Glasspool,et al. Telomerase and cancer: time to move from a promising target to a clinical reality , 2001, The Journal of pathology.
[29] M. Cobb,et al. Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.
[30] E. Parkinson,et al. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences , 1998, Oncogene.
[31] A. Bilsland,et al. Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies , 2004, Nature Clinical Practice Oncology.
[32] T. Vulliamy,et al. Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. , 2004, Blood.
[33] R. Glasspool,et al. Telomerase-directed molecular therapeutics , 2002, Expert Reviews in Molecular Medicine.
[34] F. Bachand,et al. Functional Regions of Human Telomerase Reverse Transcriptase and Human Telomerase RNA Required for Telomerase Activity and RNA-Protein Interactions , 2001, Molecular and Cellular Biology.
[35] W. Keith,et al. Expression of telomerase RNA in oesophageal and oral cancer. , 2001, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[36] W. Keith,et al. Analysis of telomerase RNA gene expression by in situ hybridization. , 2002, Methods in molecular biology.
[37] Margaret A. Strong,et al. Haploinsufficiency of mTR results in defects in telomere elongation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. Gores,et al. Bile Acids Up-regulate Death Receptor 5/TRAIL-receptor 2 Expression via a c-Jun N-terminal Kinase-dependent Pathway Involving Sp1* , 2004, Journal of Biological Chemistry.
[39] Jiangqin Zhao,et al. Involvement of NF‐Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene , 2003, FEBS letters.
[40] C. Autexier,et al. Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA. , 1996, The EMBO journal.
[41] H. Hollema,et al. Telomerase in (pre)neoplastic cervical disease. , 2000, Human pathology.
[42] A. Depaoli-Roach,et al. Dephosphorylation of Sp1 by Protein Phosphatase 1 Is Involved in the Glucose-mediated Activation of the Acetyl-CoA Carboxylase Gene* , 1996, The Journal of Biological Chemistry.
[43] K. Webster,et al. Hypoxia Regulates β-Enolase and Pyruvate Kinase-M Promoters by Modulating Sp1/Sp3 Binding to a Conserved GC Element* , 1998, The Journal of Biological Chemistry.
[44] G. Krikun,et al. Regulation of tissue factor gene expression in human endometrium by transcription factors Sp1 and Sp3. , 2000, Molecular endocrinology.
[45] J. Merchant,et al. Sp1 phosphorylation by Erk 2 stimulates DNA binding. , 1999, Biochemical and biophysical research communications.
[46] Shiaw-Yih Lin,et al. Growth/Cell Cycle Regulation of Sp1 Phosphorylation* , 1999, The Journal of Biological Chemistry.